SEA MILD BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.65 TWD | -0.52% |
|
+1.58% | -15.35% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 441 | 308.7 | 233.7 | 154.5 | 73.37 | 220.1 |
| Enterprise Value (EV) 1 | 406.1 | 326.2 | 215.7 | 140.7 | 58.15 | 217.7 |
| P/E ratio | 7,920 x | -1.92 x | -4.21 x | -2.97 x | -3.43 x | 35.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.05 x | 1.44 x | 1.12 x | 0.94 x | 0.36 x | 0.86 x |
| EV / Revenue | 1.89 x | 1.52 x | 1.04 x | 0.86 x | 0.29 x | 0.85 x |
| EV / EBITDA | -117 x | -2.38 x | -7.71 x | -6.4 x | -7.52 x | 29.5 x |
| EV / FCF | 3.96 x | -4.37 x | -15.8 x | 16.6 x | 6.53 x | 103 x |
| FCF Yield | 25.2% | -22.9% | -6.34% | 6.01% | 15.3% | 0.97% |
| Price to Book | 2.96 x | 1.61 x | 1.7 x | 1.8 x | 1.14 x | 3.13 x |
| Nbr of stocks (in thousands) | 11,308 | 19,309 | 19,309 | 19,309 | 19,309 | 19,309 |
| Reference price 2 | 39.00 | 15.99 | 12.10 | 8.000 | 3.800 | 11.40 |
| Announcement Date | 30/04/19 | 30/04/20 | 29/04/21 | 28/04/22 | 26/04/23 | 25/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 215.1 | 214.1 | 207.9 | 163.8 | 202.6 | 257 |
| EBITDA 1 | -3.48 | -136.9 | -27.96 | -21.99 | -7.737 | 7.379 |
| EBIT 1 | -7.602 | -142.8 | -36.57 | -31.99 | -11.98 | 4.833 |
| Operating Margin | -3.53% | -66.71% | -17.59% | -19.53% | -5.91% | 1.88% |
| Earnings before Tax (EBT) 1 | -8.004 | -143.5 | -47.25 | -42 | -21.48 | 6.132 |
| Net income 1 | 0.066 | -159.1 | -55.5 | -52.05 | -21.38 | 6.187 |
| Net margin | 0.03% | -74.31% | -26.7% | -31.77% | -10.55% | 2.41% |
| EPS 2 | 0.004924 | -8.337 | -2.874 | -2.696 | -1.107 | 0.3200 |
| Free Cash Flow 1 | 102.5 | -74.72 | -13.68 | 8.453 | 8.904 | 2.118 |
| FCF margin | 47.66% | -34.89% | -6.58% | 5.16% | 4.39% | 0.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 28.71% |
| FCF Conversion (Net income) | 155,319.13% | - | - | - | - | 34.24% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 30/04/19 | 30/04/20 | 29/04/21 | 28/04/22 | 26/04/23 | 25/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 17.5 | - | - | - | - |
| Net Cash position 1 | 34.9 | - | 18 | 13.8 | 15.2 | 2.38 |
| Leverage (Debt/EBITDA) | - | -0.1278 x | - | - | - | - |
| Free Cash Flow 1 | 103 | -74.7 | -13.7 | 8.45 | 8.9 | 2.12 |
| ROE (net income / shareholders' equity) | 0.04% | -80.3% | -33.6% | -46.5% | -28.4% | 9.17% |
| ROA (Net income/ Total Assets) | -1.45% | -26.3% | -7.47% | -9.58% | -4.6% | 1.74% |
| Assets 1 | -4.552 | 604.1 | 743.3 | 543.2 | 465.3 | 356.5 |
| Book Value Per Share 2 | 13.20 | 9.960 | 7.140 | 4.440 | 3.340 | 3.650 |
| Cash Flow per Share 2 | 5.580 | 2.440 | 2.700 | 2.020 | 2.100 | 2.410 |
| Capex 1 | 11.1 | 36.3 | 10.4 | 2.85 | - | 1.25 |
| Capex / Sales | 5.15% | 16.96% | 5.02% | 1.74% | - | 0.49% |
| Announcement Date | 30/04/19 | 30/04/20 | 29/04/21 | 28/04/22 | 26/04/23 | 25/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.35% | 5.76M | |
| +14.12% | 26.39B | |
| -7.12% | 16.45B | |
| -12.75% | 7.23B | |
| +4.51% | 5.89B | |
| -5.25% | 3.07B | |
| -1.99% | 2.26B | |
| -4.05% | 1.97B | |
| +28.19% | 966M | |
| +3.17% | 666M |
- Stock Market
- Equities
- 7516 Stock
- Financials Sea Mild Biotechnology Co., Ltd.